Evidence map›Paper›PMID 34348686›Full record

ArticleBMC women's health2021

Fertility sparing surgery in malignant ovarian Germ cell tumor (MOGCT): 15 years experiences.

Narges Zamani, Mohadese Rezaei Poor, Sedigheh Ghasemian Dizajmehr, Shima Alizadeh, Mitra Modares Gilani

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC women's health, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
3.3field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it, 21 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 1 country.

Narges ZamaniDepartment of Gynecologic Oncology, Vali-E-Asr Hospital, Tehran University of Medical Science, Tehran, Iran.
Mohadese Rezaei PoorDepartment of Obstetrics and Gynecology, Niknafs Hospital, Rafsanjan University of Medical Science, Rafsanjan, Iran.
Sedigheh Ghasemian DizajmehrDepartment of Obstetrics and Gynecology, Faculty of Medicine, Urmia University of Medical Science, Urmia, Iran.
Shima AlizadehDepartment of Obstetrics and Gynecology, Vali-E-Asr Hospital, Tehran University of Medical Sciences, Keshavarz Avenue, Imam Complex, Tehran, Iran. alizadeh.shima@gmail.com.
Mitra Modares GilaniDepartment of Gynecologic Oncology, Vali-E-Asr Hospital, Tehran University of Medical Science, Tehran, Iran.
University of Tehran · IRRafsanjan University of Medical Sciences · IRTehran University of Medical Sciences · IRUrmia University · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimWe aim to evaluate the reproductive outcome of fertility-sparing surgery and chemotherapy among young women diagnosed with MOGCT of any stage.

methodsIn the current retrospective study we evaluated 79 patients with malignant ovarian germ cell tumors (MOGCT) who visited at Imam Center, Vali-e-asr Hospital, Gynecologic Oncology department during 2001-2016. Reproductive outcomes (menstruation status and childbearing) followed fertility-preserving surgery and adjuvant chemotherapy by filling questionnaires. Statistical analysis was done with SPSS software, Chi-Square Tests were done, and significance was determined at P ≤ 0.05. Results among 79 young women who underwent fertility-sparing treatment, 72 patients followed up for reproductive outcome, and 7 patients excluded because of death (3 cases), XY genotyping (3 cases), and bilateral ovarian involvement (1 case). The mean age at presentation was 23 years. (Range: 19-33 years). The 5 and 10-year disease-free survival rate was 87% and 94.4%, respectively. The overall survival rate (OSR) was 94.4% at 5 and 10 years. Regular menstruation recovered in 60 of 72 patients after treatment (83%). All patients without adjuvant chemotherapy experienced regular menstruation, while normal menstruation was retrieved in 78% in the adjuvant chemotherapy group at the end of treatment. This retrieval of regular menstruation was not dependent on the age or number of chemotherapy cycles. 19 of 26 patients who attempted pregnancy were led to delivery (73%). No one required infertility treatments. The mean of chemotherapy cycles is related to a successful pregnancy.

conclusionWe showed patients with MOGCT could become pregnant and give birth if they desire. The advanced tumor stage wasn't the convincing factor for avoiding fertility preservation. Fertility sparing surgery with adjuvant chemotherapy is a safe treatment and results in a high fertility rate.

Indexed as

Fertility PreservationNeoplasms, Germ Cell and EmbryonalOvarian NeoplasmsChemotherapy, AdjuvantFemaleHumansNeoplasm StagingPregnancyRetrospective StudiesChemotherapyFertility-sparing treatmentMalignant ovarian germ cell tumorReproductive outcomeYoung adolescent

Identifiers

PMID34348686
PMCPMC8336352
OpenAlexW3189504702

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.